Mitchell Reed Smith MD PhD

Oncology•Washington, DC

Hematologic Oncology

Chief Medical Officer Follicular Lymphoma Foundation

Join to View Full Profile

2516 Q St NWSuite Q104Washington, DC 20007
Phone+1 215-603-5846

Summary

I am the Chief Medical Officer of the Follicular Lymphoma Foundation.
Formerly I was the Associate Cancer Center Director for Clinical Investigations at George Washington Cancer Center, as well as the Director of the Division of Hematology and Oncology at the Medical Faculty Associates, where I maintained my clinical practice focused on hematologic malignancies, particularly lymphoma and CLL

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1984 - 1987
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 1983 - 1984
Washington University/B-JH/SLCH ConsortiumResidency, Pathology-Anatomic and Clinical, 1981 - 1983
Washington University/B-JH/SLCH ConsortiumResidency, Pathology-Anatomic and Clinical, 1980 - 1981
Zucker School of Medicine at Hofstra/NorthwellInternship, Internal Medicine, 1979 - 1980
Case Western Reserve University School of MedicineClass of 1979

Certifications & Licensure

DC State Medical License 2017 - 2026
OH State Medical License 2012 - 2018
PA State Medical License 1993 - 2012
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Top Doctor Cleveland Magazine, 2012-2016
America's Top Doctors Castle Connolly, 2006-2014
America's Top Doctors for Cancer Castle Connolly, 2005-2013
Philadelphia Magazine Castle Connolly, 2005-2012
Super Doctor SuperDoctors.com
Join now to see all

Clinical Trials

SU5416 in Treating Patients With Refractory or Relapsed Multiple Myeloma Start of enrollment: 2000 Jun 01
Completed
Phase 2
Paclitaxel and Estramustine in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Start of enrollment: 1996 Feb 01
Completed
Phase 2
Epirubicin and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia Start of enrollment: 2003 Mar 01
Completed
Phase 2
Rituximab, Prednisone, Cyclophosphamide, Doxorubicin, Vincristine, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Previously Untreated Mantle Cell Lymphoma Start of enrollment: 2003 Nov 01
Completed
Phase 2
Safety and Efficacy Study of an Anti-CD20 Monoclonal Antibody (AME-133v) to Treat Non-Hodgkin's Lymphoma Start of enrollment: 2006 Jul 01
Completed
Phase 1
Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia Start of enrollment: 2008 Jan 15
Completed
Phase 2
Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma Start of enrollment: 2012 Aug 09
ACTIVE_NOT_RECRUITING
PHASE2
A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma Start of enrollment: 2011 Aug 01
Completed
Phase 2
Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies Start of enrollment: 2013 Mar 14
Terminated
Phase 2
p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies Start of enrollment: 2017 Apr 25
Completed
Early Phase 1
Join now to see all

Publications & Presentations

PubMed

1 citations
Carfilzomib in combination with R-CHOP for initial treatment of patients with non-germinal center diffuse large B-cell lymphoma: a multicenter, single arm, phase 1/2 s...
Brian T Hill, Pallawi Torka, Francisco Hernandez-Ilizaliturri, Robert Dean, Deepa Jagadeesh
Leukemia & Lymphoma. 2025-09-01
Follicular Lymphoma: Paving the Path to Cures Through Philanthropy.
Mitchell R Smith, Michel Azoulay, Lee M Greenberger
Clinical Lymphoma, Myeloma & Leukemia. 2025-07-01
6 citations
Randomized study of induction with bendamustine-rituximab ± bortezomib and maintenance with rituximab ± lenalidomide for MCL.
Mitchell R Smith, Opeyemi A Jegede, Peter Martin, Brian G Till, Samir S Parekh
Blood. 2024-09-05

Lectures

Loss of HDAC11 Promotes Myeloid-Derived Suppressor Cells Inhibition of T Cell Function in a Murine Lymphoma Microenvironment
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

$FDA Approves Monjuvi for Relapsed, Refractory Follicular Lymphoma$
FDA Approves Monjuvi for Relapsed, Refractory Follicular LymphomaJune 23rd, 2025
ASH Expert NHL Roundtable: Episode 1December 13th, 2019
Phase III Trial Investigating Adjuvant Cemiplimab in High-Risk CSCCAugust 6th, 2019
Join now to see all